We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 05, 2022

Aumolertinib vs Gefitinib as First-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Exon 19 Deletion or L858R Mutations

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
J. Clin. Oncol 2022 May 17;[EPub Ahead of Print], S Lu, X Dong, H Jian, J Chen, G Chen, Y Sun, Y Ji, Z Wang, J Shi, J Lu, S Chen, D Lv, G Zhang, C Liu, J Li, X Yu, Z Lin, Z Yu, Z Wang, J Cui, X Xu, J Fang, J Feng, Z Xu, R Ma, J Hu, N Yang, X Zhou, X Wu, C Hu, Z Zhang, Y Lu, Y Hu, L Jiang, Q Wang, R Guo, J Zhou, B Li, C Hu, W Tong, H Zhang, L Ma, Y Chen, Z Jie, Y Yao, L Zhang, W Jie, W Li, J Xiong, X Ye, J Duan, H Yang, M Sun, C Sun, H Wei, C Li, SM Ali, VA Miller, Q Wu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading